Hormonal treatments for adenomyosis

Luigi Fedele, Stefano Bianchi, Frontino G, Giada Frontino
Best practice & research. Clinical obstetrics & gynaecology · 2007 · vol. 22(2) , pp. 333–339 · doi:10.1016/j.bpobgyn.2007.07.006 · PMID:17765017 · W2107517606
review OA: closed CC0 ⤵ 38 in-corpus citations
View on OpenAlex View on PubMed View at publisher
⚙ AI-generated summary by claude@2026-06, 2026-06-07 ⓘ

This paper reviews hormonal treatments for adenomyosis, discussing their efficacy and safety profiles for managing the condition.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

Abstract

Like endometriosis and uterine myomas, adenomyosis presents the typical characteristics of oestrogen-dependent diseases. The medical treatment of adenomyosis is based on the hormonal dependency of the disease and its strongly debated similarities with endometriosis. Infact, despite the evident differences between the two conditions, the therapies that treat endometriosis effectively have also been successful for the treatment of adenomyosis. Although the two diseases have distinct epidemiological features, they have the same 'target tissue' for hormonal therapy, namely ectopic endometrium. Recognized approaches are systemic hormonal treatments, which are generally used for endometriosis and are capable of suppressing the oestrogenic induction of the disease, and local hormonal treatment that targets the ectopic endometrium directly. Gonadotropin-releasing hormone agonists, danazol and intrauterine levonorgestrel- or danazol-releasing devices have been used in the treatment of adenomyosis. Despite the solid rational basis for its hormonal treatment, few studies have been performed on medical therapy for adenomyosis.

My notes (saved in your browser only)

Condition tags

endometriosisadenomyosis

MeSH descriptors

Endometriosis Danazol Danazol Endometriosis Estrogen Antagonists Estrogen Antagonists Female Gonadotropin-Releasing Hormone Gonadotropin-Releasing Hormone Humans Intrauterine Devices Levonorgestrel Levonorgestrel

Citation neighborhood

Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. [ expand to 2 hops ] — adds papers reached through this work's immediate citers/citees. Heavier; up to 60 extra dots.

References (53)

Cited by (39)

Source provenance

europepmc
last seen: 2026-07-25T06:15:30.875455+00:00
openalex
last seen: 2026-06-10T17:14:06.276822+00:00
pubmed
last seen: 2026-05-13T22:14:48.452140+00:00
License: CC0 · commercial use OK